Defining skeletal muscle resident progenitors and their cell fate potentials
Citations Over TimeTop 10% of 2013 papers
Abstract
The satellite cell is the major tissue-resident stem cell underlying muscle regeneration; however, multiple non-satellite myogenic progenitors as well as non-myogenic populations that support the muscle regenerative process have been identified. PW1 is expressed in satellite cells as well as in a subset of interstitial cells with myogenic potential termed PICs (PW1+ interstitial cells). Microarray profiling revealed that PICs express a broad range of genes common to mesenchymal stem cells, whereas satellite cells express genes consistent with a committed myogenic progenitor. Isolated PICs from both young and adult muscles can differentiate into smooth and skeletal muscle and fat whereas satellite cells are restricted to a skeletal muscle fate. We demonstrate that the adipogenic potential of PICs corresponds to a subpopulation that expresses platelet derived growth factor receptor alpha (PDGFRα) and overlaps with the recently described interstitial adipogenic progenitors. By contrast, PICs with myogenic potential do not express PDGFRα. Moreover, we observe a discrete and transient population of juvenile PICs based upon SCA1 expression that disappears by 3 weeks of postnatal development coincident with a switch in the cellular and genetic mechanisms underlying postnatal muscle growth.
Related Papers
- → Local Inhibition of Complement Improves Mesenchymal Stem Cell Viability and Function After Administration(2016)62 cited
- → Mesenchymal stem cell therapy in treatment of erectile dysfunction: Autologous or allogeneic cell sources?(2014)32 cited
- → Mesenchymal Stem/Stromal Cells: ASSESSING THE SAFETY AND TOXICITY OF VERY HIGH DOSES OF ALLOGENEIC HUMAN UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELLS(2023)1 cited
- → Mesenchymal Stem/Stromal Cells: THE EFFECTS OF ADIPOSE TISSUE MESENCHYMAL STEM CELLS (AT-MSCS) ON IMMUNOLOGICAL PATTERNS IN FEMALES WITH MULTIPLE SCLEROSIS(2022)
- → Mesenchymal Stem/Stromal Cells: COMMENCEMENT OF FIRST-IN-HUMAN FOR CLINICAL TRIAL OF ADIPOSE TISSUE DERIVED ALLOGENEIC MESENCHYMAL STEM CELL (ADMSC) SHEETS FOR RETINAL DISEASES(2023)